CJC-1295 (no DAC) + Ipamorelin + Tesamorelin common uses, half-life, side effects and more

This blend combines three growth hormone secretagogues in a single injection. Tesamorelin and CJC-1295 no DAC both act on the growth hormone releasing hormone receptor. Ipamorelin acts on a separate ghrelin receptor pathway. People use the stack to raise their own growth hormone and IGF-1 for body composition, visceral fat, sleep, and recovery. Only single-agent tesamorelin is FDA-approved. That approval covers excess belly fat in adults with HIV lipodystrophy and nothing else. CJC-1295 no DAC and ipamorelin are unapproved research chemicals. No approved product contains this three-part blend.

• Raising the body's own growth hormone and IGF-1
• Visceral and abdominal fat protocols
• Body composition and lean mass
• Sleep quality and recovery
• Off-label metabolic use outside HIV lipodystrophy

Once daily for labeled tesamorelin. Community triple-stack protocols use one evening injection 5 nights per week or daily. Cycles often run 8 to 12 weeks with a break.

Separate-vial protocols inject tesamorelin 1.28 to 1.4 mg under the skin once daily plus 100 to 300 mcg CJC-1295 no DAC and 100 to 300 mcg ipamorelin in the same evening session. A legacy 2 mg tesamorelin dose is still common. The blend is also sold as one premixed research vial of 12 mg split into 6 mg tesamorelin, 3 mg CJC-1295 no DAC, and 3 mg ipamorelin. That is a 2:1:1 mass ratio. People usually dose the premix to keep CJC-1295 no DAC and ipamorelin near 100 to 150 mcg. That means a 0.4 to 0.6 mg total nightly dose. That dose delivers only 200 to 300 mcg tesamorelin and stays well under tesamorelin's own 1.28 to 1.4 mg label. Reaching a labeled tesamorelin dose from the premix instead delivers roughly 640 to 700 mcg of each of the other two peptides. Chasing the legacy 2 mg dose delivers about 1 mg of each. Both amounts run several times above the usual 100 to 300 mcg ranges.

• Read the vial label rather than the blend name because a 6/3/3 mg premix locks a 2:1:1 ratio and one dose moves all three peptides together
• Separate tesamorelin and CJC plus ipamorelin vials let tesamorelin follow its own label while the shorter peptides stay in range
• Give the blend under the skin because labeled tesamorelin specifies abdominal injection with site rotation
• A product labeled only CJC-1295 needs identity checking because the DAC-linked version is a different molecule that lasts days instead of minutes

No combination pharmacokinetic study exists. The three peptides clear at different rates. Tesamorelin has a labeled half-life of 8 to 11 minutes. Ipamorelin has a measured human intravenous half-life of about 2 hours. No human study has measured the CJC-1295 no DAC half-life.

Labeled tesamorelin has formulation-specific storage that a research blend does not inherit. Egrifta WR stays at room temperature for 7 days after mixing. Egrifta SV is discarded right after mixing. A premixed research blend carries no approved storage guidance.

• Injection-site redness, pain, swelling, itching, or lumps
• Flushing, warmth, dizziness, headache, or drowsiness after a dose
• Water retention, joint aches, tingling hands, or carpal tunnel symptoms
• Higher blood sugar, reduced insulin sensitivity, or IGF-1 above the age-adjusted range
• Nausea, vomiting, bloating, insomnia, or low potassium reported in intravenous ipamorelin trials
• Rash, hives, swelling, or trouble breathing can signal an allergic reaction

• CJC-1295 (no DAC)

  100 to 300 mcg per separate injection or 100 to 150 mcg per common 0.4 to 0.6 mg premix dose

• Ipamorelin

  100 to 300 mcg per separate injection or 100 to 150 mcg per common 0.4 to 0.6 mg premix dose

• Tesamorelin

  1.28 to 1.4 mg per labeled separate injection or 200 to 300 mcg per common 0.4 to 0.6 mg premix dose

Tesamorelin and CJC-1295 no DAC both activate the growth hormone releasing hormone receptor on the pituitary. Tesamorelin is the full 44 amino acid hormone with a chemical cap that slows its breakdown. CJC-1295 no DAC is a shortened 29 amino acid version protected by four sequence changes. Ipamorelin instead activates the ghrelin receptor and drives growth hormone release through a separate pathway. All three raise a pulse of the body's own growth hormone that lifts IGF-1 from the liver. Combining a releasing hormone with a ghrelin agonist rests on older human work showing the two signal types can raise the growth hormone pulse more together than alone. Those studies used other releasing peptides rather than this exact trio. No study shows the blend outperforms its components.

Direct evidence for this three-part blend is very low. No randomized trial, human pharmacokinetic study, animal study, or case series has tested the combination. Only tesamorelin carries trial evidence. Two randomized studies reduced excess abdominal fat in adults with HIV lipodystrophy. That evidence does not transfer to healthy users, to nonprescription research blends, or to protocols outside that population. Ipamorelin has one human pharmacokinetic study by vein and a failed postoperative ileus trial. CJC-1295 no DAC has no published human study at all. Older human work supports the general idea that a releasing hormone and a releasing peptide can amplify each other. That work never used this trio and does not validate the blend.

• All three components are banned in sport at all times under WADA class S2
• Active or prior cancer is a reason to avoid this blend because tesamorelin is contraindicated in active malignancy and growth hormone signaling can support cell growth
• Pregnancy and breastfeeding should avoid it because tesamorelin caused fluid on the brain in rat offspring and the other two components have no reproductive data
• Diabetes, prediabetes, insulin resistance, high IGF-1, or untreated sleep apnea raises the risk because tesamorelin alone more than tripled the odds of crossing into diabetes
• Ipamorelin carries FDA-flagged compounding safety concerns, serious adverse events including death reported with intravenous use, and no subcutaneous human safety study
• Reaching a labeled tesamorelin dose from a 6/3/3 mg premixed vial delivers about 640 mcg each of CJC-1295 no DAC and ipamorelin above their usual 100 to 300 mcg range